Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.

Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA.

Cancer Res. 2019 Jul 30. pii: canres.0698.2019. doi: 10.1158/0008-5472.CAN-19-0698. [Epub ahead of print]

PMID:
31362929
2.

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model.

Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD.

FEBS Open Bio. 2019 Oct;9(10):1689-1704. doi: 10.1002/2211-5463.12702. Epub 2019 Sep 7.

3.

Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.

Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U.

Cell Chem Biol. 2019 Sep 19;26(9):1240-1252.e11. doi: 10.1016/j.chembiol.2019.06.003. Epub 2019 Jun 27.

PMID:
31257184
4.

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM.

Clin Cancer Res. 2019 Sep 15;25(18):5686-5701. doi: 10.1158/1078-0432.CCR-18-3382. Epub 2019 Jun 21.

PMID:
31227503
5.

An immunoproteomic approach to characterize the CAR interactome and signalosome.

Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, Yoder S, Berglund A, Koomen JM, Haura EB, Abate-Daga D.

Sci Signal. 2019 Feb 12;12(568). pii: eaap9777. doi: 10.1126/scisignal.aap9777.

6.

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.

Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U.

Sci Rep. 2019 Jan 24;9(1):606. doi: 10.1038/s41598-018-37174-6.

7.

Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeutics.

Boutchueng-Djidjou M, Rix U, Haura EB.

Expert Rev Proteomics. 2018 Sep;15(9):697-699. doi: 10.1080/14789450.2018.1521276. Epub 2018 Sep 28. No abstract available.

8.

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.

Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K.

Mol Cancer Ther. 2018 Dec;17(12):2796-2810. doi: 10.1158/1535-7163.MCT-18-0602. Epub 2018 Sep 21.

PMID:
30242092
9.

Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.

Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, Novakova S, Kinose F, Remsing Rix LL, Haura EB, Koomen JM, Rix U.

Mol Cell Proteomics. 2018 Dec;17(12):2434-2447. doi: 10.1074/mcp.RA118.000713. Epub 2018 Sep 14.

PMID:
30217950
10.

Unraveling the rewired network.

Palve V, Kuenzi BM, Rix U.

Nat Chem Biol. 2018 Aug;14(8):746-747. doi: 10.1038/s41589-018-0083-7. No abstract available.

PMID:
29942077
11.

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.

Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE.

Oncotarget. 2017 Aug 24;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28.

12.

Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.

Hoffman MA, Fang B, Haura EB, Rix U, Koomen JM.

J Proteome Res. 2018 Jan 5;17(1):63-75. doi: 10.1021/acs.jproteome.7b00329. Epub 2017 Nov 22.

13.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM.

Mol Cancer Ther. 2018 Jan;17(1):73-83. doi: 10.1158/1535-7163.MCT-17-0196. Epub 2017 Nov 13.

14.

Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.

Phadke M, Remsing Rix LL, Smalley I, Bryant AT, Luo Y, Lawrence HR, Schaible BJ, Chen YA, Rix U, Smalley KSM.

Mol Oncol. 2018 Jan;12(1):74-88. doi: 10.1002/1878-0261.12152. Epub 2017 Nov 23.

15.

Polypharmacology-based ceritinib repurposing using integrated functional proteomics.

Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U.

Nat Chem Biol. 2017 Dec;13(12):1222-1231. doi: 10.1038/nchembio.2489. Epub 2017 Oct 9.

16.

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P.

Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31.

17.

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.

Wright G, Golubeva V, Remsing Rix LL, Berndt N, Luo Y, Ward GA, Gray JE, Schonbrunn E, Lawrence HR, Monteiro ANA, Rix U.

ACS Chem Biol. 2017 Jul 21;12(7):1883-1892. doi: 10.1021/acschembio.7b00147. Epub 2017 Jun 7.

18.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

19.

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions.

Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, Aisner DL, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD.

Oncotarget. 2017 Feb 14;8(7):11114-11126. doi: 10.18632/oncotarget.14366.

20.

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.

Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U.

Cell Chem Biol. 2016 Dec 22;23(12):1490-1503. doi: 10.1016/j.chembiol.2016.10.011. Epub 2016 Nov 17.

21.

APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data.

Kuenzi BM, Borne AL, Li J, Haura EB, Eschrich SA, Koomen JM, Rix U, Stewart PA.

J Proteome Res. 2016 Dec 2;15(12):4747-4754. Epub 2016 Oct 21.

22.

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN.

Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.

23.

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.

Li J, Fang B, Kinose F, Bai Y, Kim JY, Chen YA, Rix U, Koomen JM, Haura EB.

Mol Cancer Ther. 2016 Feb;15(2):334-42. doi: 10.1158/1535-7163.MCT-15-0444. Epub 2016 Jan 15.

24.

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.

Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U.

ACS Chem Biol. 2015 Dec 18;10(12):2680-6. doi: 10.1021/acschembio.5b00368. Epub 2015 Oct 5.

25.

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.

Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9.

26.

Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies.

Haura EB, Beg AA, Rix U, Antonia S.

Cancer Immunol Res. 2015 Jul;3(7):714-20. doi: 10.1158/2326-6066.CIR-15-0094. Epub 2015 Jun 16. Review.

27.

Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.

Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM.

Methods. 2015 Jun 15;81:41-9. doi: 10.1016/j.ymeth.2015.03.006. Epub 2015 Mar 14.

28.

Targeting a cell state common to triple-negative breast cancers.

Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM.

Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664.

29.

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB.

Cancer Res. 2014 Dec 15;74(24):7217-7228. doi: 10.1158/0008-5472.CAN-14-0505. Epub 2014 Oct 27.

30.

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

Haura EB, Rix U.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju250. doi: 10.1093/jnci/dju250. Print 2014 Sep. No abstract available.

31.

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.

Gridling M, Ficarro SB, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto JA, Superti-Furga G, Bennett KL, Rix U.

Mol Cancer Ther. 2014 Nov;13(11):2751-62. doi: 10.1158/1535-7163.MCT-14-0152. Epub 2014 Sep 4.

32.

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.

Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM.

Oncotarget. 2014 May 30;5(10):2947-61.

33.

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U.

ACS Chem Biol. 2014 Feb 21;9(2):353-8. doi: 10.1021/cb400660a. Epub 2013 Nov 20.

34.

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.

Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB.

Mol Syst Biol. 2013 Nov 5;9:705. doi: 10.1038/msb.2013.61.

35.

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, Cerny-Reiterer S, Burkard TR, Jäger U, Melo JV, Bennett KL, Valent P, Superti-Furga G.

PLoS One. 2013 Oct 10;8(10):e77155. doi: 10.1371/journal.pone.0077155. eCollection 2013.

36.

A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.

Chamrád I, Rix U, Stukalov A, Gridling M, Parapatics K, Müller AC, Altiok S, Colinge J, Superti-Furga G, Haura EB, Bennett KL.

J Proteome Res. 2013 Sep 6;12(9):4005-17. doi: 10.1021/pr400309p. Epub 2013 Aug 20.

37.

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.

Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12414-9. doi: 10.1073/pnas.1220674110. Epub 2013 Jul 8.

38.

A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.

Borgdorff V, Rix U, Winter GE, Gridling M, Müller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G, Wagner SN.

Oncogene. 2014 May 8;33(19):2531-9. doi: 10.1038/onc.2013.185. Epub 2013 Jun 3.

PMID:
23728343
39.

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.

Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G.

Nat Chem Biol. 2012 Nov;8(11):905-912. doi: 10.1038/nchembio.1085. Epub 2012 Sep 30.

40.

Systems biology analysis of protein-drug interactions.

Colinge J, Rix U, Bennett KL, Superti-Furga G.

Proteomics Clin Appl. 2012 Jan;6(1-2):102-16. doi: 10.1002/prca.201100077. Epub 2011 Dec 27. Review.

PMID:
22213655
41.

Compound immobilization and drug-affinity chromatography.

Rix U, Gridling M, Superti-Furga G.

Methods Mol Biol. 2012;803:25-38. doi: 10.1007/978-1-61779-364-6_3.

PMID:
22065216
42.

Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine.

Brandt O, Mildner M, Egger AE, Groessl M, Rix U, Posch M, Keppler BK, Strupp C, Mueller B, Stingl G.

Nanomedicine. 2012 May;8(4):478-88. doi: 10.1016/j.nano.2011.07.005. Epub 2011 Aug 10.

PMID:
21839058
43.

An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

Winter GE, Rix U, Lissat A, Stukalov A, Müllner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G.

Mol Cancer Ther. 2011 Oct;10(10):1846-56. doi: 10.1158/1535-7163.MCT-11-0100. Epub 2011 Jul 18.

44.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

PMID:
21680801
45.

A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib.

Burkard TR, Rix U, Breitwieser FP, Superti-Furga G, Colinge J.

PLoS Comput Biol. 2010 Nov 18;6(11):e1001001. doi: 10.1371/journal.pcbi.1001001.

46.

MASPECTRAS 2: An integration and analysis platform for proteomic data.

Ubaida Mohien C, Hartler J, Breitwieser F, Rix U, Remsing Rix L, Winter GE, Thallinger GG, Bennett KL, Superti-Furga G, Trajanoski Z, Colinge J.

Proteomics. 2010 Jul;10(14):2719-22. doi: 10.1002/pmic.201000075.

PMID:
20455215
47.

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB.

Nat Chem Biol. 2010 Apr;6(4):291-9. doi: 10.1038/nchembio.332. Epub 2010 Feb 28.

48.

Dasatinib in solid tumors.

Kim LC, Rix U, Haura EB.

Expert Opin Investig Drugs. 2010 Mar;19(3):415-25. doi: 10.1517/13543781003592097. Review.

PMID:
20113198
49.

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.

Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G.

Leukemia. 2010 Jan;24(1):44-50. doi: 10.1038/leu.2009.228. Epub 2009 Nov 5.

PMID:
19890374
50.

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.

Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P.

Eur J Clin Invest. 2009 Dec;39(12):1098-109. doi: 10.1111/j.1365-2362.2009.02206.x. Epub 2009 Sep 9.

PMID:
19744184

Supplemental Content

Support Center